GEN and GNMSF Related Headlines

Go Back

GEN and GNMSF Related Press Releases

Go Back

Jul 22, 2015 08:27AM Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL
Jul 10, 2015 11:54AM Major Shareholder Announcement for Genmab A/S
Jul 9, 2015 01:53PM Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
Jul 7, 2015 07:40AM Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
Jun 5, 2015 11:54AM Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
Jun 2, 2015 01:28AM Genmab Gains License to Antibody Panel Targeting CD19
May 21, 2015 10:14AM Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA
May 19, 2015 01:40AM Genmab Enters Commercial DuoBody(r) Technology Agreement With BioNTech in Field of Immuno-oncology
May 13, 2015 05:10PM HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
May 12, 2015 11:11AM Genmab Announces Financial Results for the First Quarter of 2015
May 6, 2015 07:14AM First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)
Apr 27, 2015 10:26AM Genmab Announces Phase III Study of Arzerra(r) Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
Apr 16, 2015 09:46AM Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen
Mar 26, 2015 02:09PM Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab
Mar 18, 2015 10:14AM Genmab Acquires Antibody Assets from iDD Biotech
Mar 16, 2015 06:36AM Genmab Retains Partial Rights for HuMax-TAC-ADC - Will Not Exercise Co-development Right
Mar 11, 2015 01:16PM Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015

GEN and GNMSF Related SEC Filings

Go Back